French luxury goods company LVMH has reached an agreement to acquire Marcolin’s 49% stake in their joint-venture, Thélios, increasing the former’s shareholding in the high-end Italian optical frames manufacturer. Read more
EssilorLuxottica owns 99.7% of GrandVision, paving way for delisting
EssilorLuxottica has announced it now holds an almost 100% stake in GrandVision after the completion of a mandatory public offer period, opening the door to delist shares in the optical retailer on the Amsterdam Stock Exchange. Read more
Menicon sets sights on consumer connection with new MyMiru website
Japanese contact lens manufacturer Menicon has launched a new consumer-facing website that’s now accessible in Australia. Read more
ProVision CEO Steven Johnston to call it a day after 10 years
Outgoing ProVision CEO Mr Steven Johnston believes the future of independent optometry in Australia is bright if practices continue to embrace technology that allows the time to offer a patient experience that can’t be replicated anywhere else. Read more
Prominent figures to oversee Vision Eye Institute’s new Future Vision Foundation
The Vision Eye Institute (VEI) has launched the new not-for-profit Future Vision Foundation to support ophthalmic research, as well as the Vision Hospital Group to bring its day surgery network under one banner, to mark its 20th anniversary. Read more
New findings ‘alter forever how we think of MIGS’ – Dr Ike Ahmed
Ivantis has revealed new data from its five-year HORIZON pivotal trial showing its Hydrus Microstent device lowers the rate of visual field loss by 47% versus cataract surgery alone. Read more
Harnessing the potential of your contact lens portfolio
Attracting and retaining patients with contact lens products has become increasingly difficult with the rise of online retailers. But Menicon Australia is one major manufacturer choosing to stick by independents with a portfolio spanning across daily disposables and specialty contact lenses.
Major leap towards human trials for Western Australia’s PYC Therapeutics
Australian biotechnology company PYC Therapeutics has advanced its RNA platform closer to human trials after determining safe and well tolerated doses of its co-lead drug candidate for retinitis pigmentosa 11 (RP11) in monkeys. Read more
Dr Rene Hessling replaces Joe Redner as Zeiss ANZ managing director
After a career spanning more than 21 years at Zeiss, Mr Joe Redner has departed the company, handing the reins of the Australasia business to Dr Rene Hessling. Read more
Hoya launches Oliver Wolfe Junior frames
Hoya Vision Care Australia & New Zealand has unveiled a new Oliver Wolfe Junior frame collection – suitable for the company’s new myopia control spectacle lens – in response to practice requests to extend the brand’s popular adult range. Read more